All In MedTech

Device Trial Radar · NCT07246902

Mobilization and Outcomes After Venous Closure

MOVE - Mobilization and Outcomes After VEnous Closure - A Prospective Registry of Real-World Outcomes/Usage/Evidence for the MYNX CONTROL™ VENOUS Vascular Closure Device 6F-12F

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

339

Actual

Start

Nov 24, 2025

Primary completion

Aug 26, 2026

Study completion Aug 26, 2026

Sponsor

Lead sponsor
Cordis US Corp.Not on our public-company list
Sponsor type
Industry
Collaborators
NAMSA
First posted
Nov 24, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.

Conditions

  • Venous Vascular Closure
  • Electrophysiology Study

Interventions

  • MYNX CONTROLTM VENOUS Vascular Closure DeviceDevice

    The MYNX CONTROLTM VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing 6F to 12F procedural sheaths, with single or multiple access sites in one or both limbs. MCV VCD is designed to achieve femoral vein hemostasis via delivery of the GRIP TECHNOLOGY™ sealant (an extravascular, water-soluble synthetic hydrogel), using a balloon catheter in conjunction with a standard procedural sheath. The sealant is made of a polyethylene glycol (PEG) material which expands upon contact with subcutaneous fluids to seal the venotomy and is resorbed by the body within 30 days. The MCV VCD is supplied with a 10ml locking syringe used for balloon inflation and deflation. The catheter shaft has a silicone lubricant to facilitate insertion and withdrawal into compatible sheaths.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of patients with same day discharge (SDD) and without subsequent hospitalization/intervention for access-site complicationsTime frame: From time of index procedure through end of following day (within 48 hours)
  2. Rate of access-site complicationsTime frame: From time of study device introduction at first access site through 14 days post-procedure

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Stanford University School of Medicine

    Palo Alto, California

  • South Denver Cardiology

    Littleton, Colorado

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.